Source: Annual Congress 2002 - Community-acquired pneumonia - aetiology and management
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Hagberg, S. Jenkins, R. Nusrat (Goteborg, Sweden; Bridgewater, United States Of America). Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia. Eur Respir J 2002; 20: Suppl. 38, 3485

Member's Comments

No comment yet.

Related content which might interest you: Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Outpatient treatment of community-acquired pneumonia in the elderly Source: Eur Respir J 2002; 20: Suppl. 38, 355s Year: 2002 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Azithromycin in treatment of atypical pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 716s Year: 2004 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012